Mounjaro 0.5 mg: is this the right dose for you?

Why 0.5 mg doesn't exist in the Mounjaro dose range

The confusion is understandable. Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for weight management) uses a dose scale where 0.25 mg and 0.5 mg are genuine, early steps in the titration. Tirzepatide, the active ingredient in Mounjaro, works across a completely different dose range because it is a dual GIP and GLP-1 receptor agonist. Activating two receptors means the effective dose window sits higher, starting at 2.5 mg. You can find a clear breakdown of how the dose increments compare on the Mounjaro dose guide.

If a seller online is advertising "Mounjaro 0.5 mg", treat that as a serious red flag. It suggests either a mislabelled product, a counterfeit pen, or a simple confusion of brand names. The MHRA has warned publicly about fake and unlicensed weight-loss pens circulating via social media and unverified websites, any legitimate UK supply of Mounjaro will only ever offer the six licensed strengths.

Getting the dose right matters clinically, not just for results. Starting at too high a strength increases the chance of gastrointestinal side effects; starting at too low (or at a dose that doesn't exist) provides neither benefit nor safety. A prescriber's job is to find the appropriate point on the schedule for your situation.

The real decision: 2.5 mg or 5 mg, and when does the next step happen?

Treatment with Mounjaro begins at 2.5 mg for the first four weeks. This isn't a therapeutic dose in the sense of producing meaningful weight loss on its own, its job is to let your body adjust to the medicine and reduce early gastrointestinal discomfort. Think of it as the system settling in.

After four weeks, the prescriber typically moves to 5 mg, then onwards through 7.5, 10, 12.5, and up to 7.5 mg as subsequent steps, with roughly four-week intervals between each increase. The schedule is set by the prescriber based on tolerability and clinical progress, it isn't automatic. Some people stay longer at one strength; others tolerate the full titration with minimal side effects.

A practical note on routine: the pen lives in the fridge, but once you've settled into a weekly schedule, most people find a fixed day works best, tying it to something consistent makes it easy to track. The injection technique guide covers what to do if you're new to self-injecting.

The NICE appraisal of tirzepatide (TA1026) confirms the full dose schedule as part of its recommendation for adults with a BMI of 35 or above and at least one weight-related condition, with lower BMI thresholds for certain ethnic backgrounds.

What happens if you're on semaglutide at 0.5 mg and considering switching?

If you are currently taking semaglutide at 0.5 mg (whether Ozempic for diabetes or Wegovy at that stage of titration) and you're asking about Mounjaro, the question is whether switching makes clinical sense for you. That is genuinely a prescriber conversation, not a self-referral decision. The two medicines share a mechanism in part (GLP-1 activation) but differ in how broadly they act, their side-effect profiles at equivalent stages, and the evidence base for each.

The full Mounjaro overview covers the clinical evidence in more detail. For cost context, the Mounjaro cost page explains how private pricing works and what a transparent price should include. Worth reading before you make any decision.

One thing to note: Ozempic is licensed for type 2 diabetes, not weight management. If you're using it off-label for weight loss, a switch to a licensed weight-management medicine is worth discussing with a clinician. The NHS tirzepatide medicine page is a reliable starting point for understanding what Mounjaro involves.

How a prescriber at nume decides which strength to prescribe

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not automated software processing a form. The prescriber looks at your BMI, any weight-related conditions, your medical history, and current medicines before deciding whether Mounjaro is suitable and, if so, which strength to start at.

The starting point for almost everyone is 2.5 mg, per the licensed schedule. Transfer patients arriving from another provider with evidence of their current dose may be considered for a different starting point, but that still requires clinical review. Dose increases are never automatic, each step is assessed. You can explore treatment options or ask our clinical team a question through the consultation page.